Duration of Invega's Pharmacologic Effect After Discontinuation
Invega (paliperidone) continues to exert pharmacologic effects for approximately 4-6 weeks after the last oral dose, based on its 23-hour elimination half-life and the time required to reach subtherapeutic plasma concentrations. For long-acting injectable formulations, the duration extends substantially longer—up to 126 days for paliperidone palmitate monthly (PP1M) and even longer for the 3-month (PP3M) and 6-month (PP6M) formulations 1, 2.
Oral Invega (Paliperidone Extended-Release)
The FDA label specifies that oral paliperidone has a terminal elimination half-life of approximately 23 hours, with steady-state concentrations attained within 4-5 days of dosing 1.
Clinically meaningful effects persist for approximately 4-6 weeks after discontinuation because:
- It takes approximately 5 half-lives (5 × 23 hours = ~5 days) for 97% drug elimination from plasma
- However, receptor occupancy and clinical effects lag behind plasma clearance
- Therapeutic dopamine D2 receptor blockade may persist beyond plasma detection
Long-Acting Injectable Formulations
Paliperidone Palmitate Monthly (PP1M/Invega Sustenna)
- Release duration: up to 126 days after a single injection 2
- Mean half-life: 24-49 days depending on dose 3
- Peak plasma concentrations occur at 13 days post-injection 2
- Clinical effects persist 6-8 weeks after the last monthly injection in most patients
Paliperidone Palmitate 3-Month (PP3M/Invega Trinza)
- Substantially longer duration than PP1M due to extended-release formulation
- Clinical effects can persist 3-4 months after the last injection
- Studies show patients maintained stability for extended periods after discontinuation 4, 5
Paliperidone Palmitate 6-Month (PP6M/Invega Hafyera)
- Longest duration of action among all formulations
- Clinical effects may persist 6-8 months after the last injection 6
Critical Clinical Considerations
Withdrawal symptoms and discontinuation effects require gradual tapering extending over more than 1 month 7. Abrupt discontinuation of antipsychotics, including paliperidone, can cause:
- Dyskinesias
- Parkinsonian symptoms
- Dystonias
- Neuroleptic malignant syndrome
- Rebound psychosis
Monitor patients closely for 8-12 weeks after discontinuation, as this represents the highest risk period for relapse 8. One study found the greatest relapse risk occurs in the first 8-12 weeks after stopping antipsychotic medication 8.
For long-acting injectables, the extended pharmacokinetic profile means withdrawal effects may emerge weeks to months after the last injection 9, 10. A case report documented tardive dyskinesia persisting over 6 years after stopping PP3M, highlighting that adverse effects can outlast therapeutic benefits 10.
Practical Management Algorithm
If discontinuing oral paliperidone:
- Taper over 2-4 weeks minimum 7
- Monitor weekly for first month
- Continue monitoring every 2 weeks for additional 2 months
- Watch for psychotic symptom recurrence, movement disorders, and withdrawal symptoms
If discontinuing long-acting injectable:
- Do NOT administer next scheduled injection
- Consider bridging with oral antipsychotic during transition if switching medications
- Monitor monthly for 3-6 months (PP1M), 4-8 months (PP3M), or 6-12 months (PP6M)
- Re-escalate dosing if withdrawal symptoms cause patient distress 7
Relapse prevention requires maintaining treatment for at least 12 months after remission 11, and discontinuation decisions should involve mental health specialists, patients, and families 11.